Lido Advisors’s AbbVie ABBV Stock Holding History

Lido Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$101K	Hold	400	–	–	﹤0.01%	2039
2026 Q1	$87K	Buy	+400	New	+$88.7K	﹤0.01%	1875

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Lido Advisors's ABBV Position: Q2 2026 in Review

Lido Advisors increased its AbbVie (ABBV) stake by 6.3% in Q2 2026, buying an estimated $5.86M and bringing the position to 459,683 shares worth $116M. The position accounts for 0.31% of the portfolio, ranked #46.

Lido Advisors first reported a position in ABBV in Q1 2016 and has held it in 42 quarters since. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Lido Advisors held 459,683 shares of AbbVie worth $116M as of Q2 2026.
Lido Advisors bought 27,218 AbbVie shares in Q2 2026, an estimated $5.86M.
AbbVie made up 0.31% of Lido Advisors's portfolio in Q2 2026, its #46 holding.
Lido Advisors first reported a position in AbbVie in Q1 2016 and has held it in 42 quarters since.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.